APOE-stratified genome-wide association analyses provide insights into the genetic etiology of Alzheimers's disease.

APOE-stratified GWAS identified new genetic signals for Alzheimer's disease risk, including DDHD1, with effects specific to APOE ε4 and ε2 carrier status.

• Why it matters: Understanding how APOE variants influence Alzheimer's risk is crucial because they remain the strongest genetic factors, yet their mechanisms and impact on treatment efficacy are poorly understood.
• What they did: The study conducted genome-wide association analyses stratified by APOE ε4 and ε2 carrier status, revealing new risk loci such as HP1BP3, SLC50A1, PTPRC, NPAS3, DDHD1, CHST9, SMYD2, PRAMEF1, and GFRA1.
• The result: Findings like the protective effect of DDHD1 in ε4 carriers may inform targeted therapies, improve clinical trial strategies, and enhance understanding of APOE-related mechanisms in neurodegeneration.